Join TB Alliance and partners at the 56th Union World Conference on Lung Health, taking place in Copenhagen from 18 – 21 November 2025. Find out more about our presentations and events at the conference.
Events Calendar
MONDAY, NOVEMBER 17
Side Event | Innovate, Integrate, Impact: A Symposium on New Tools to End TB
13:30 – 19:00 CET
Join a meeting dedicated to TB tools ahead of the Union World Conference on Health Lung 2025. This event will feature the annual meetings of the Working Group for New TB Drugs, the Working Group for New TB Vaccines, and the New Diagnostics Working Group.
For meeting information and registration, please click here.
TUESDAY, NOVEMBER 18
Workshop | UPSKILL TB: Strengthening of drug-resistant TB management through implementation of global open online training
10:10 – 13:10 CET | Room: B4A
The workshop aims to introduce Upskill-TB (Universal Platform in Skill Improvement for Learning New TB Regimen), an innovative and interactive global digital training platform designed to enhance healthcare workers’ ability to provide quality care for people affected by DR-TB, starting from courses on using the new BPaL/M regimen. A dedicated hands-on session will allow participants to experience Upskill-TB firsthand, explore its key course modules and interactive learning methods, and provide real-time feedback to inform future improvement and broader implementation in TB care programs.
Please see the online program for additional details.
Community Connect | Catalysing community power: Driving demand and accountability in drug-resistant TB care
12:30 – 13:15 CET | Meeting Room 19
With the introduction of shorter, all-oral treatments like BPaL and BPaLM for DR-TB, communities have become increasingly central to ensuring timely treatment access, building awareness, and driving uptake. This session represents the next phase of the Fast Track the Cure (FTTC) initiative, originally launched in 2023, and moving beyond awareness-raising activities and focusing explicitly on demonstrating a catalytic approach for community-led demand creation and monitoring, implemented through strategic, collaborative actions across five high-burden countries: India, Nigeria, Pakistan, Peru, and Bangladesh.
Please see the online program for additional details.
E-Poster | Active TB drug safety of novel drug-resistant regimens: Challenges and solutions in a decentralised setting
13:35 – 13:40 CET | Balcony 2, Screen 8
The BPaL-based regimen is known both for its effectiveness and manageable toxicity. In the Philippines, the regimen transitioned from use under operational research to programmatic scale-up in a decentralized setting. Challenges in active TB drug safety monitoring and management (aDSM) paved the way to targeted support for peripheral facilities.
Please see the online program for additional details.
TB Science E-Poster | Comparing LAM to other sputum-based biomarkers in NC-009 trial
13:35 – 13:40 CET | Balcony 2, Screen 10
New mycobacterial markers are needed to shorten and improve outcome predictability of TB drug trials, which still rely on sputum culture, a resource-intensive procedure with results taking up to 8 weeks. PATHFAST TB LAM Ag assay (LAM), a semi-automated chemiluminescent enzyme immunoassay that quantifies mycobacterial lipoarabinomannan in sputum within 1 hour, appears as a promising alternative, but has been only evaluated in patients treated for up to 2 weeks.
Please see the online program for additional details.
TB Science E-Poster | Prospective prediction of TBAJ-876-PaL phase 2 clinical outcomes in NC-009 trial via a multi-model framework
13:35 – 13:40 CET | Balcony 2, Screen 10
Successful preclinical-to-clinical translation can accelerate development of safer, more effective tuberculosis regimens. Here, we leveraged a multimodal model-based framework to prospectively predict clinical outcomes of the promising diarylquinoline TBAJ-876, in combination with pretomanid and linezolid (TBAJ-876-PaL), in Phase 2 NC-009 trial (NCT06058299), ahead of trial read-outs.
Please see the online program for additional details.
Workshop | Navigating the complexity of TB: A digital clinical decision support system for optimised care pathways
15:00 – 18:00 CET | Meeting Room 17
ManageTB is an advanced Clinical Decision Support System (CDSS), developed to support public and private sector clinicians in delivering precise, guideline-compliant care for DR-TB. Participants will acquire a working understanding of the ManageTB tool’s application in the management of complex DR-TB cases. The workshop will also highlight transferable insights for the replication of such digital health interventions in other national contexts.
Please see the online program for additional details.
WEDNESDAY, NOVEMBER 19
Symposium Session | Progress towards a PAN-TB regimen: Insights from the PAN-TB collaboration’s XBQS phase 2b/c Trial
9:15 – 10:45 CET
The symposium’s overall objective is to contribute to the TB regimen development community’s efforts to develop new TB drugs and regimens by presenting the final PAN-TB trial results and key learnings from the innovations implemented.
Please see the online program for additional details.
Satellite Session | Long-Acting TB Regimens and the Future of Treatment
12:15 – 13:45 CET | B2A
This session will explore the promise of LAIs in the TB landscape—and the key hurdles to their development and scale-up. Presenters will explore scientific advancements, clinical development pathways, and the critical enablers required for real-world success, including health system integration, policy alignment, and community engagement. As TB programs face mounting challenges, this discussion will consider how LAIs could play a pivotal role in transforming the future of TB care, accelerating a shift toward simpler, more effective TB treatment.
Please see the online program for additional details.
Late-Breaker | The Union/CDC Late-Breaker Session – Clinical Trial Advances in TB: HIV Co-Infection, Pediatric Meningitis, and New Drugs
15:55 – 17:25 CET | Auditorium
Included in this session is a results presentation the Phase 1 IMPAACT study. In female children with RR-TB, the PK of a single dose of pretomanid was characterized with adequate precision to guide weight-based doses. Exposures were comparable to those in adults. Safety/tolerability and acceptability were favorable. A multidose study of a pretomanid-containing regimen is planned in female and male children with RR-TB.
Please see the online program for additional details.
THURSDAY, NOVEMBER 20
Community Connect | Youth-led initiatives and using technology to drive access to better TB service and treatments
8:00 – 8:45 CET | Meeting Room 19
This session will explore how youth leadership and digital innovation are shaping a more inclusive and responsive tuberculosis (TB) response, particularly in the context of rolling out newer, shorter regimens for drug-resistant TB (DR-TB) such as BPaL and BPaLM. These advancements in treatment must be matched by equally innovative, community-driven approaches to awareness, demand generation, and accountability.
Please see the online program for additional details.
FRIDAY, NOVEMBER 21
Oral Abstract Presentation | Advancing TB care: Innovations in drugs, vaccines, diagnostics and treatment
9:15 – 10:45 CET | B4B
Included in this presentation is an oral abstract sharing the results of the NC-009 Pan-Phase 2 clinical trial. TBAJ-876 is a second-generation diarylquinoline with greater in-vitro potency, favorable preclinical safety, and treatment-shortening demonstrated in murine-models, relative to bedaquiline. The NC-009 study evaluates the safety and efficacy of 3 doses of TBAJ-876 in combination with pretomanid and linezolid after 8 weeks of treatment in comparison with standard-of-care and BPaL.
Please see the online program for additional details.